Abstract:Chronic inflammation triggers development of metabolic disease, and pulmonary tuberculosis (TB) generates chronic systemic inflammation. Whether TB induced-inflammation impacts metabolic organs and leads to metabolic disorder is ill defined. The liver is the master regulator of metabolism and to determine the impact of pulmonary TB on this organ we undertook an unbiased mRNA and protein analyses of the liver in mice with TB and reanalysed published data on human disease. Pulmonary TB led to upregulation of genes in the liver related to immune signalling and downregulation of genes encoding metabolic processes. In liver, IFN signalling pathway genes were upregulated and this was reflected in increased biochemical evidence of IFN signalling, including nuclear location of phosphorylated Stat-1 in hepatocytes. The liver also exhibited reduced expression of genes encoding the gluconeogenesis rate-limiting enzymes Pck1 and G6pc. Phosphorylation of CREB, a transcription factor controlling gluconeogenesis was drastically reduced in the livers of mice with pulmonary TB as was phosphorylation of other glucose metabolism-related kinases, including GSK3a, AMPK, and p42. In support of the upregulated IFN signalling being linked to the downregulated metabolic functions in the liver, we found suppression of gluconeogenic gene expression and reduced CREB phosphorylation in hepatocyte cell lines treated with interferons. The impact of reduced gluconeogenic gene expression in the liver was seen when infected mice were less able to convert pyruvate, a gluconeogenesis substrate, to the same extent as uninfected mice. Infected mice also showed evidence of reduced systemic and hepatic insulin sensitivity. Similarly, in humans with TB, we found that changes in a metabolite-based signature of insulin resistance correlates temporally with successful treatment of active TB and with progression to active TB following exposure. These data support the hypothesis that TB drives interferon-mediated alteration of hepatic metabolism resulting in reduced gluconeogenesis and drives systemic reduction of insulin sensitivity. Tuberculosis (TB) is a worldwide disease with a substantial proportion of undiagnosed cases. Control of TB is mediated by a protective cellular immune response which is also chronic, inflammatory and systemic. Chronic inflammation can disrupt metabolism and compromise the organs key to maintaining health–such as the liver. The extent to which pulmonary TB can disrupt the metabolic function of the liver is ill defined. We have used a mouse model of pulmonary TB to examine the changes occurring in the liver when immunity is first being expressed in the lung. We found that pulmonary TB leads to upregulation of immune-related signalling pathways in liver cells and that TB infected mice have altered glucose metabolism. Reanalysing published metabolic data from humans, we find that a metabolic signature associated with insulin resistance separates those with TB from healthy subjects and alters with time to progression and resolution of TB, thereby indicating glucose metabolism disruption occurs during TB in humans. These data are important because we show that TB disrupts liver glucose metabolism, and this is critical to understanding the interplay between TB and metabolic disease.

The impact of an oral glucose load on IFN-γ-release in persons infected with Mycobacterium tuberculosis

The Diagnostic Efficiency Evaluation of Combination Tuberculosis Interferon-Gamma Release Assay with Human Leukocyte Antigen-G for Tuberculosis

High Glucose and Carbonyl Stress Impair HIF-1-Regulated Responses and the Control of Mycobacterium tuberculosis in Macrophages

Relevance of antigen-induced IL-6 and mitogen-induced or spontaneous IFN-γ secretions in whole blood cultures for detection of Mycobacterium tuberculosis infection and disease

Impact of hyperglycemia on tuberculosis treatment outcomes: a cohort study

Patients with type 1 diabetes mellitus have impaired IL-1β production in response to Mycobacterium tuberculosis

Interleukin-6 and Mycobacterium tuberculosis dormancy antigens improve diagnosis of tuberculosis

The In-Vitro Interferon-Gamma Release Assay for the Diagnosis of Tuberculosis and Mycobacterium Tuberculosis Infections

Evaluation of Gamma Interferon Release Assays Using Mycobacterium Tuberculosis Antigens for Diagnosis of Latent and Active Tuberculosis in Mycobacterium Bovis Bcg-Vaccinated Populations

Persistently elevated T cell interferon-γ responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report

[Interferon Gamma Release Assay Request Indications: From Laboratory to Clinical Perspective]

Immunological aspects of host-pathogen crosstalk in the co-pathogenesis of diabetes and latent tuberculosis

Diagnostic Accuracy of Interferon Gamma-Induced Protein 10 mRNA Release Assay for Tuberculosis

Evaluation of the Diagnostic Potential of IP-10 and IL-2 As Biomarkers for the Diagnosis of Active and Latent Tuberculosis in a BCG-Vaccinated Population

Evaluation of Diagnostic Performance of Three Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis

Impact of the interferon-γ release assay and glomerular filtration rate on the estimation of active tuberculosis risk before bronchoscopic examinations: a retrospective pilot study

IgG glycosylation associates with risk of progression from latent to active tuberculosis

Tuberculosis Specific Interferon-Gamma Production in a Current Refugee Cohort in Western Europe

Interferon-Gamma Release Assay Combined with Renal Indicators to Reduce the False-Negativity of Latent Tuberculosis Infection in End-Stage Renal Disease with Hemodialysis Patients

High-sensitive and rapid detection of Mycobacterium tuberculosis infection by IFN-γ release assay among HIV-infected individuals in BCG-vaccinated area

Altered hepatic metabolic landscape and insulin sensitivity in response to pulmonary tuberculosis